



## Company Overview

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

## Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem's Board of Directors

Jan 3 2022, 4:10 PM EST

## Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update

Dec 15 2021, 4:05 PM EST

## Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th

Dec 2 2021, 4:05 PM EST

## Stock Overview

Symbol	ENZ
Exchange	NYSE
Market Cap	160.44m
Last Price	\$3.31
52-Week Range	\$2.61 - \$4.85

01/14/2022 04:00 PM EST

## Investor Relations

[IR@enzo.com](mailto:IR@enzo.com)

## Management Team

### Elazar Rabbani, PhD

Chairman of the Board of Directors & Chief Scientific Officer

### Hamid Erfanian

Chief Executive Officer

### Barry W. Weiner

President

### David Bench

Chief Financial Officer

### Kara Cannon

Chief Commercial Officer

### Dieter Schapfel, MD

Chief Medical Officer

---

## Enzo Biochem, Inc.

527 Madison Avenue  
New York, NY 10022

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.